Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:51 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2761–2784 of 13,632 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatologic Disorders Clear all

Conditions: HER2/Neu Positive, Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions: Entinostat, Laboratory Biomarker Analysis, Lapatinib Ditosylate, Trastuzumab; Drug · Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Carcinoma, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer
Interventions: Exemestane, Laboratory Biomarker Analysis, Oophorectomy, Quality-of-Life Assessment, Radiation Therapy, Tamoxifen, Triptorelin; Drug · Other · Procedure + 1 more
Lead sponsor: ETOP IBCSG Partners Foundation; Network
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 3,066 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2024
U.S. locations: 480
States / cities: Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 323 more

Conditions: Acne Vulgaris
Interventions: CD0271 0.3% / CD1579 2.5%, CD0271 0.1% / CD1579 2.5%, Topical Gel Vehicle; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 12 Years and older
Enrollment: 503 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 25
States / cities: Birmingham, Alabama • Mobile, Alabama • Hot Springs, Arkansas + 22 more

Conditions: Metastatic Breast Cancer, HER2 Low Breast Carcinoma, HER2-negative Breast Cancer, Breast Cancer, Breast Cancer Female
Interventions: Elacestrant, Trastuzumab Deruxtecan; Drug
Lead sponsor: Kristina A. Fanucci; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2038
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cancer
Interventions: capecitabine, cisplatin; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: Paclitaxel, Trastuzumab, Pertuzumab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 5
States / cities: Boston, Massachusetts • Milford, Massachusetts • South Weymouth, Massachusetts

Conditions: Arthritis, Psoriatic
Interventions: golimumab, Placebo; golimumab; Biological
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 407 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 18
States / cities: Huntsville, Alabama • La Jolla, California • Upland, California + 15 more

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Carcinoma, Colorectal Carcinoma, Malignant Solid Neoplasm, Prostate Carcinoma, Stage I Colorectal Cancer AJCC v8, Stage I Prostate Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
Interventions: Exercise Intervention (supervised), Exercise Intervention (unsupervised), Informational Intervention, Questionnaire Administration; Behavioral · Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 35 Years to 80 Years
Enrollment: 496 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Malignant Melanoma
Interventions: Vincristine Sulfate Liposomes Injection; Drug
Lead sponsor: Acrotech Biopharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer, Postoperative Pain, Opioid Use, Local Anesthesia
Interventions: Pectoral Nerve Block, Surgery without Nerve Block; Procedure
Lead sponsor: Main Line Health; Other
Eligibility: 18 Years and older · Female only
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Neoplasms
Interventions: PF-04518600, PF-04518600 plus PF-05082566; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 24
States / cities: Los Angeles, California • Newport Beach, California • Santa Monica, California + 9 more

Conditions: Actinic Keratoses
Interventions: ingenol mebutate 0.015%, dermasil lotion; Drug · Other
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Tumors, Neoplasm Metastasis
Interventions: Rapamycin (sirolimus), Grapefruit Juice; Drug · Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Psoriasis
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: Exemestane, Celecoxib, Correlative studies; Drug · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Dystrophic Epidermolysis Bullosa
Interventions: Not listed
Lead sponsor: Shire; Industry
Eligibility: Not listed
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 3
States / cities: Chicago, Illinois • New York, New York • Cincinnati, Ohio

Conditions: Diabetic Foot Ulcer
Interventions: Noraxon myoRESEARCH™ Software Gait Analysis Evaluation and Orthotic; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acne Vulgaris
Interventions: CD5789 25 µg/g cream, CD5789 50 µg/g cream, CD5789 100 µg/g cream, Tazarotene 0.1% gel, Vehicle cream; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 12 Years to 35 Years
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 24
States / cities: Birmingham, Alabama • Glendale, California • Marina del Rey, California + 21 more

Conditions: Breast Cancer
Interventions: OMM prior to SLNB; Procedure
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Melanoma and Other Malignant Neoplasms of Skin, Basal Cell Carcinoma of Skin, Squamous Cell Carcinoma of the Skin
Interventions: Skin lesion diagnostic device evaluation; Device
Lead sponsor: VeriSkin, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 6
States / cities: Pleasanton, California • Walnut Creek, California • Tampa, Florida + 3 more

Conditions: Breast Cancer
Interventions: Hypofractionation; Radiation
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 2
States / cities: Scottsdale, Arizona • Rochester, Minnesota

Conditions: Breast Cancer, Breast Neoplasms
Interventions: Not listed
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 20 Years to 74 Years · Female only
Enrollment: 3,300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2044
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Breast Cancer
Interventions: brachytherapy; Radiation
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Breast Cancer
Interventions: RGT-419B, RGT-419B in combination with hormonal therapy; Drug
Lead sponsor: Regor Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 8
States / cities: La Jolla, California • Los Angeles, California • Port Saint Lucie, Florida + 5 more

Search by objective public record fields.

Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris

ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer

Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors

DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC

A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis

EXERCISING TOGETHER for Couples Coping With Cancer

Pharmacokinetic Study of Liposomal Vincristine in Patients With Malignant Melanoma & Hepatic Dysfunction

PECS Block in Partial Mastectomy for Postoperative Pain Control

Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566

Treatment of Actinic Keratoses (AK) on the Face

Rapamycin With Grapefruit Juice for Advanced Malignancies

Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study

Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer

Short Term Observational Study in DEB Patients

Noraxon myoRESEARCH™ Software Gait Analysis Evaluation and Orthotic Gait Correction in Reducing Diabetic Foot Ulceration Or Subsequent Amputation in Patients With a History of a Diabetic Foot Ulceration

Dose Range Study of CD5789 in Acne Vulgaris

Impact of Osteopathic Manipulative Medicine on Sentinal Lymph Node Biopsy Dye and Tracer Uptake

TruScore Standalone Clinical Study

A Trial of 15 Fraction vs 25 Fraction Pencil Beam Scanning Proton Radiotherapy After Mastectomy in Patients Requiring Regional Nodal Irradiation

Carolina Breast Cancer Study Phase 4

Evaluation of Accelerated Partial Breast Brachytherapy

FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer